Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAOX | Q6QHF9 | 5/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | CPT2 | P23786 | 1/20 | 0.36 |
| ▸ | ACLY | P53396 | 1/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9386368 | 0.97 | PAOX (0.52) | PAOXALDH1A1ACHELMNASLC15A2 | |
| SCHEMBL8898949 | 0.97 | PAOX (0.52) | PAOXALDH1A1ACHELMNASLC15A2 | |
| SCHEMBL26042660 | 0.97 | PAOX (0.52) | PAOXALDH1A1ACHELMNASLC15A2 | |
| SCHEMBL1785870 | 0.97 | PAOX (0.52) | PAOXALDH1A1ACHELMNASLC15A2 | |
| SCHEMBL5819774 | 0.97 | PAOX (0.52) | PAOXALDH1A1ACHELMNASLC15A2 | |
| SCHEMBL1781286 | 0.92 | ALDH1A1 (0.47) | PAOXALDH1A1ACHELMNASLC15A2 | |
| SCHEMBL8733126 | 0.89 | TSHR (0.50) | PAOXALDH1A1LMNASLC15A2TDP1 | |
| SCHEMBL15457429 | 0.81 | MAPT (0.41) | ALDH1A1LMNATDP1FFAR1CPT2 | |
| SCHEMBL681141 | 0.80 | — | — | |
| SCHEMBL25705851 | 0.80 | PAOX (0.50) | PAOXALDH1A1ACHELMNASLC15A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119925246-A | Composition with effects of controlling oil, removing acnes and astringing pores, skin care product and preparation method thereof | 湖北省吉美化妆品有限公司 | 2025-05-06 | — | — | CN | disclosed |
| US-20240018156-A1 | SPIROCYCLIC COMPOUNDS | C4 THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20230357180-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230226207-A1 | Camptothecin Drug Having High-Stability Hydrophilic Connecting Unit And Conjugate Thereof | SYSTIMMUNE, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230159488-A1 | APPLICATION OF HETEROCYCLIC COMPOUND CONTAINING AT LEAST TWO SULFUR ATOMS IN PREPARING NANO-VACCINE AND PREPARED NANO-VACCINE | Suzhou WEAST Biotechnology Co., Ltd. (CN) | 2023-05-25 | — | — | US | disclosed |
| EP-3562921-B1 | LUBRICATING COMPOSITION INCLUDING N-ALKYLATED DIANILINE | LUBRIZOL CORP (US) | 2022-04-27 | — | — | EP | disclosed |
| CN-110114448-B | Lubricating composition with alkylated naphthylamines | 路博润公司 | 2022-03-04 | — | — | CN | disclosed |
| US-11162048-B2 | Lubricating composition with alkylated naphthylamine | THE LUBRIZOL CORPORATION (US) | 2021-11-02 | — | — | US | disclosed |
| EP-3562922-B1 | LUBRICATING COMPOSITION WITH ALKYLATED NAPHTHYLAMINE | LUBRIZOL CORP (US) | 2021-02-03 | — | — | EP | disclosed |
| EP-3681875-A1 | CYCLIC PEPTIDE ANTIBIOTICS | H. Hoffnabb-La Roche Ag (CH) | 2020-07-22 | — | — | EP | disclosed |
| US-20130184282-A1 | IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS | NOVARTIS AG (CH) | 2013-07-18 | — | — | US | disclosed |
| US-8476224-B2 | Macrocycles and their uses | NOVARTIS AG (US) | 2013-07-02 | — | — | US | disclosed |
| US-20130102611-A1 | IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS | NOVARTIS AG (CH) | 2013-04-25 | — | — | US | disclosed |
| US-8324239-B2 | Furopyridine compounds and uses thereof | NOVARTIS AG (CH) | 2012-12-04 | — | — | US | disclosed |
| US-20120015907-A1 | Furopyridine compounds and uses thereof | NOVARTIS AG (CH) | 2012-01-19 | — | — | US | disclosed |
| US-20110117147-A1 | COOLING SENSATION AGENT COMPOSITION AND SENSORY STIMULATION AGENT COMPOSITION | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2011-05-19 | — | — | US | disclosed |
| US-7868135-B2 | Compositions of lipopeptide antibiotic derivatives and methods of use thereof | BIOWEST THERAPEUTICS INC. (CA) | 2011-01-11 | — | — | US | disclosed |
| US-7868135-B2 | Compositions of lipopeptide antibiotic derivatives and methods of use thereof | BIOWEST THERAPEUTICS INC. (CA) | 2011-01-11 | — | — | US | disclosed |
| WO-2009123355-A2 | COOLING SENSATION AGENT COMPOSITION AND SENSORY STIMULATION AGENT COMPOSITION | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2009-10-08 | — | — | WO | disclosed |
| US-20090012320-A1 | Method for the Production of Olefins from Carbonyl Compounds | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159488-A1 | APPLICATION OF HETEROCYCLIC COMPOUND CONTAINING AT LEAST TWO SULFUR ATOMS IN PREPARING NANO-VACCINE AND PREPARED NANO-VACCINE | CD4, NFATC1, CTSA | PAOX 2639/4885ALDH1A1 4510/4885ACHE 1508/4885 |
| US-20230226207-A1 | Camptothecin Drug Having High-Stability Hydrophilic Connecting Unit And Conjugate Thereof | SLC7A1, CD44, DCLRE1A | PAOX 2834/4885ALDH1A1 2318/4885ACHE 4866/4885 |
| US-20110117147-A1 | COOLING SENSATION AGENT COMPOSITION AND SENSORY STIMULATION AGENT COMPOSITION | TRPA1, HRH1, HRH2 | PAOX 2315/4885ALDH1A1 520/4885ACHE 1079/4885 |
| US-20240018156-A1 | SPIROCYCLIC COMPOUNDS | CRBN, XIAP, RBX1 | PAOX 685/4885ALDH1A1 1971/4885ACHE 4008/4885 |
| US-20120015907-A1 | Furopyridine compounds and uses thereof | CYP3A5, QDPR, DPYD | PAOX 1319/4885ALDH1A1 178/4885ACHE 469/4885 |
| US-20090012320-A1 | Method for the Production of Olefins from Carbonyl Compounds | COASY, FASN, PTGES | PAOX 603/4885ALDH1A1 165/4885ACHE 2608/4885 |
| US-20230357180-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | STUB1, MDM2, USP30 | PAOX 1625/4885ALDH1A1 3735/4885ACHE 4175/4885 |
| US-20130102611-A1 | IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS | PTGIR, ACVR1, PTGFR | PAOX 505/4885ALDH1A1 2869/4885ACHE 4714/4885 |
| US-20130184282-A1 | IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS | PTGIR, GPR68, ACVR1 | PAOX 462/4885ALDH1A1 3576/4885ACHE 4344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.